Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T P Lin

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Trials|June 16, 2022
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]Xuan Ying Poh, I Russel Lee, Clarissa Lim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2021
Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)Sean Wei Xiang Ong, Calvin J Chiew, Li Wei Ang, et al.
Emerging Infectious Diseases|September 16, 2009
Entomologic and virologic investigation of Chikungunya, SingaporeLee-Ching Ng, Li-Kiang Tan, Cheong-Huat Tan, et al.
EMBO Molecular Medicine|March 6, 2012
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoproteinYiu-Wing Kam, Fok-Moon Lum, Teck-Hui Teo, et al.
JAMA|April 15, 2010
2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in SingaporeMark I C Chen, Vernon J M Lee, Wei-Yen Lim, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variantsXuan Ying Poh, Shirley Y Y Mah, Aileen Y Y Yeoh, et al.
Lancet (London, England)|March 21, 2020
Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measuresRachael Pung, Calvin J Chiew, Barnaby E Young, et al.
BMC Infectious Diseases|December 5, 2012
Teacher led school-based surveillance can allow accurate tracking of emerging infectious diseases - evidence from serial cross-sectional surveys of febrile respiratory illness during the H1N1 2009 influenza pandemic in SingaporeShu E Soh, Alex R Cook, Mark I C Chen, et al.
NPJ Digital Medicine|June 30, 2022
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimensAgata Blasiak, Anh T L Truong, Alexandria Remus, et al.
Scientific Reports|April 6, 2021
Clinical features and predictors of severity in COVID-19 patients with critical illness in SingaporeSer Hon Puah, Barnaby Edward Young, Po Ying Chia, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Trials|June 16, 2022
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]Xuan Ying Poh, I Russel Lee, Clarissa Lim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2021
Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)Sean Wei Xiang Ong, Calvin J Chiew, Li Wei Ang, et al.
Emerging Infectious Diseases|September 16, 2009
Entomologic and virologic investigation of Chikungunya, SingaporeLee-Ching Ng, Li-Kiang Tan, Cheong-Huat Tan, et al.
EMBO Molecular Medicine|March 6, 2012
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoproteinYiu-Wing Kam, Fok-Moon Lum, Teck-Hui Teo, et al.
JAMA|April 15, 2010
2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in SingaporeMark I C Chen, Vernon J M Lee, Wei-Yen Lim, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variantsXuan Ying Poh, Shirley Y Y Mah, Aileen Y Y Yeoh, et al.
Lancet (London, England)|March 21, 2020
Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measuresRachael Pung, Calvin J Chiew, Barnaby E Young, et al.
BMC Infectious Diseases|December 5, 2012
Teacher led school-based surveillance can allow accurate tracking of emerging infectious diseases - evidence from serial cross-sectional surveys of febrile respiratory illness during the H1N1 2009 influenza pandemic in SingaporeShu E Soh, Alex R Cook, Mark I C Chen, et al.
NPJ Digital Medicine|June 30, 2022
The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimensAgata Blasiak, Anh T L Truong, Alexandria Remus, et al.
Scientific Reports|April 6, 2021
Clinical features and predictors of severity in COVID-19 patients with critical illness in SingaporeSer Hon Puah, Barnaby Edward Young, Po Ying Chia, et al.
Pageof 16